No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib
Jacqueline C Barrientos, Peter Hillmen, Gilles Salles, Jeff Sharman, Stephan Stilgenbauer, Oksana Gurtovaya, Guan Xing, Bianca Ruzicka, Pankaj Bhargava, Paolo Ghia, John M Pagel, Jacqueline C Barrientos, Peter Hillmen, Gilles Salles, Jeff Sharman, Stephan Stilgenbauer, Oksana Gurtovaya, Guan Xing, Bianca Ruzicka, Pankaj Bhargava, Paolo Ghia, John M Pagel
Abstract
The advent of novel B-cell receptor pathway targeting agents like ibrutinib dramatically changed management of B-cell malignancies. However, with concomitant anticoagulation (AC) and antiplatelet (AP) therapy, ibrutinib is associated with increased bleeding. This post hoc analysis aimed to determine the role of AC/AP therapy in patients with idelalisib-treated B-cell malignancies and to establish if it contributes to increased bleeding events. Data from two idelalisib trials (rituximab ± idelalisib in chronic lymphocytic leukemia [CLL] and idelalisib monotherapy in indolent non-Hodgkin lymphoma [iNHL]) were analyzed. Antithrombotic therapy was common (36%-63%), with comparable bleeding incidence across treatment groups (14%-19%; p = 0.56). Bleeding events of grade ≥3 occurred in 0.9% and 3.2% of the idelalisib-treated CLL and iNHL cohorts, respectively. Our findings demonstrate no increase in bleeding events with simultaneous AC/AP treatment and idelalisib use. Hemorrhagic risk is prevalent in these patients and an important consideration when evaluating available treatment options. ClinicalTrials.gov identifiers: NCT01539512 and NCT01282424.
Keywords: Hemorrhage; PI3K inhibitor; anticoagulant; antiplatelet; thrombocytopenia.
Source: PubMed